Indian Immunologicals clocks all-time high revenue of Rs 1,586 crore in FY26
Over the past decade, IIL has maintained a strong growth trajectory, registering a compound annual growth rate (CAGR) of 16%
Over the past decade, IIL has maintained a strong growth trajectory, registering a compound annual growth rate (CAGR) of 16%
The company has also been named among global sustainability leaders for the 7th year in a row in the Dow Jones Sustainability Index in the Emerging Markets category
Dr. Reddy’s included in S&P Global’s Sustainability Yearbook for the 2nd year and Bloomberg Gender-Equality Index for the 5th year in a row
The company will market it under the brand name Molflu
Subscribe To Our Newsletter & Stay Updated